Exelixis, GlaxoSmithKline deal

GSK exercised an option to license exclusive rights to develop and commercialize EXEL's XL880 under a 2002 deal that was amended in 2005 (see BioCentury, Nov. 4, 2002, & Jan. 17, 2005). EXEL will rec...